OR WAIT null SECS
Biotage has announced a strategic collaboration with Shandong Yingsheng Biotechnology for the development of clinical MS applications in China.
Biotage has announced in a June 4, 2019 press release a strategic collaboration with Shandong Yingsheng Biotechnology (Yingsheng) for the development of clinical mass spectrometry (MS) applications in China.
Under the terms of the collaboration, Biotage will provide systems and consumables within its analytical chemistry portfolio to Yingsheng for sale, alongside Yingsheng’s own brand and other products and technical solutions, on the Chinese market.
“This collaboration opens up a market not previously available to Biotage, and we believe that Biotage, together with Yingsheng, have good opportunities to be successful in this market environment,” said Torben Jörgensen, CEO and president of Biotage, in a press release. “Clinical MS detection can be used in varied applications like vitamin, hormone, and new born screening. MS detection owns clear advantages in sensitivity and accuracy compared to traditional methods. Due to cost, complexity, and technical reasons, it was not widely available before. This new joint effort is to provide a complete solution for this market. For Biotage, particularly, it is also a great possibility to strengthen our efforts in China within analytical chemistry.”